Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone

Elizabeth R. Sharlow, Karthik Giridhar, Courtney R. LaValle, Jun Chen, Stephanie Leimgruber, Rebecca Barrett, Karla Bravo-Altamirano, Peter Wipf, John S. Lazo, Q. Jane Wang

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Protein kinase D (PKD) is a novel family of serine/threonine kinases targeted by the second messenger diacylglycerol. It has been implicated in many important cellular processes and pathological conditions. However, further analysis of PKD in these processes is severely hampered by the lack of a PKD-specific inhibitor that can be readily applied to cells and in animal models. Wenow report the discovery of the first potent and selective cell-active small molecule inhibitor for PKD, benzoxoloazepinolone (CID755673). This inhibitor was identified from the National Institutes of Health small molecule repository library of 196,173 compounds using a human PKD1 (PKCμ)-based fluorescence polarization high throughput screening assay. CID755673 suppressed half of the PKD1 enzyme activity at 182 nM and exhibited selective PKD1 inhibition when compared with AKT, polo-like kinase 1 (PLK1), CDK activating kinase (CAK), CAMKIIα, and three different PKC isoforms. Moreover, it was not competitive with ATP for enzyme inhibition. In cell-based assays, CID755673 blocked phorbol ester-induced endogenous PKD1 activation in LNCaP cells in a concentration-dependent manner. Functionally, CID755673 inhibited the known biological actions of PKD1 including phorbol ester-induced class IIa histone deacetylase 5 nuclear exclusion, vesicular stomatitis virus glycoprotein transport from the Golgi to the plasma membrane, and the ilimaquinone-induced Golgi fragmentation. Moreover, CID755673 inhibited prostate cancer cell proliferation, cell migration, and invasion. In summary, our findings indicate that CID755673 is a potent and selective PKD1 inhibitor with valuable pharmacological and cell biological potential.

Original languageEnglish (US)
Pages (from-to)33516-33526
Number of pages11
JournalJournal of Biological Chemistry
Volume283
Issue number48
DOIs
StatePublished - Nov 28 2008
Externally publishedYes

Fingerprint

Phorbol Esters
Assays
High-Throughput Screening Assays
Small Molecule Libraries
Enzyme inhibition
Vesicular Stomatitis
Molecules
Fluorescence Polarization
Histone Deacetylases
Protein-Serine-Threonine Kinases
Diglycerides
National Institutes of Health (U.S.)
Cell proliferation
Enzyme activity
Second Messenger Systems
Pathologic Processes
Enzymes
Cell membranes
Viruses
Cell Movement

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Sharlow, E. R., Giridhar, K., LaValle, C. R., Chen, J., Leimgruber, S., Barrett, R., ... Wang, Q. J. (2008). Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. Journal of Biological Chemistry, 283(48), 33516-33526. https://doi.org/10.1074/jbc.M805358200

Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. / Sharlow, Elizabeth R.; Giridhar, Karthik; LaValle, Courtney R.; Chen, Jun; Leimgruber, Stephanie; Barrett, Rebecca; Bravo-Altamirano, Karla; Wipf, Peter; Lazo, John S.; Wang, Q. Jane.

In: Journal of Biological Chemistry, Vol. 283, No. 48, 28.11.2008, p. 33516-33526.

Research output: Contribution to journalArticle

Sharlow, ER, Giridhar, K, LaValle, CR, Chen, J, Leimgruber, S, Barrett, R, Bravo-Altamirano, K, Wipf, P, Lazo, JS & Wang, QJ 2008, 'Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone', Journal of Biological Chemistry, vol. 283, no. 48, pp. 33516-33526. https://doi.org/10.1074/jbc.M805358200
Sharlow, Elizabeth R. ; Giridhar, Karthik ; LaValle, Courtney R. ; Chen, Jun ; Leimgruber, Stephanie ; Barrett, Rebecca ; Bravo-Altamirano, Karla ; Wipf, Peter ; Lazo, John S. ; Wang, Q. Jane. / Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. In: Journal of Biological Chemistry. 2008 ; Vol. 283, No. 48. pp. 33516-33526.
@article{4fe9707a6cf3478a92d5b91f7eaa45c3,
title = "Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone",
abstract = "Protein kinase D (PKD) is a novel family of serine/threonine kinases targeted by the second messenger diacylglycerol. It has been implicated in many important cellular processes and pathological conditions. However, further analysis of PKD in these processes is severely hampered by the lack of a PKD-specific inhibitor that can be readily applied to cells and in animal models. Wenow report the discovery of the first potent and selective cell-active small molecule inhibitor for PKD, benzoxoloazepinolone (CID755673). This inhibitor was identified from the National Institutes of Health small molecule repository library of 196,173 compounds using a human PKD1 (PKCμ)-based fluorescence polarization high throughput screening assay. CID755673 suppressed half of the PKD1 enzyme activity at 182 nM and exhibited selective PKD1 inhibition when compared with AKT, polo-like kinase 1 (PLK1), CDK activating kinase (CAK), CAMKIIα, and three different PKC isoforms. Moreover, it was not competitive with ATP for enzyme inhibition. In cell-based assays, CID755673 blocked phorbol ester-induced endogenous PKD1 activation in LNCaP cells in a concentration-dependent manner. Functionally, CID755673 inhibited the known biological actions of PKD1 including phorbol ester-induced class IIa histone deacetylase 5 nuclear exclusion, vesicular stomatitis virus glycoprotein transport from the Golgi to the plasma membrane, and the ilimaquinone-induced Golgi fragmentation. Moreover, CID755673 inhibited prostate cancer cell proliferation, cell migration, and invasion. In summary, our findings indicate that CID755673 is a potent and selective PKD1 inhibitor with valuable pharmacological and cell biological potential.",
author = "Sharlow, {Elizabeth R.} and Karthik Giridhar and LaValle, {Courtney R.} and Jun Chen and Stephanie Leimgruber and Rebecca Barrett and Karla Bravo-Altamirano and Peter Wipf and Lazo, {John S.} and Wang, {Q. Jane}",
year = "2008",
month = "11",
day = "28",
doi = "10.1074/jbc.M805358200",
language = "English (US)",
volume = "283",
pages = "33516--33526",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "48",

}

TY - JOUR

T1 - Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone

AU - Sharlow, Elizabeth R.

AU - Giridhar, Karthik

AU - LaValle, Courtney R.

AU - Chen, Jun

AU - Leimgruber, Stephanie

AU - Barrett, Rebecca

AU - Bravo-Altamirano, Karla

AU - Wipf, Peter

AU - Lazo, John S.

AU - Wang, Q. Jane

PY - 2008/11/28

Y1 - 2008/11/28

N2 - Protein kinase D (PKD) is a novel family of serine/threonine kinases targeted by the second messenger diacylglycerol. It has been implicated in many important cellular processes and pathological conditions. However, further analysis of PKD in these processes is severely hampered by the lack of a PKD-specific inhibitor that can be readily applied to cells and in animal models. Wenow report the discovery of the first potent and selective cell-active small molecule inhibitor for PKD, benzoxoloazepinolone (CID755673). This inhibitor was identified from the National Institutes of Health small molecule repository library of 196,173 compounds using a human PKD1 (PKCμ)-based fluorescence polarization high throughput screening assay. CID755673 suppressed half of the PKD1 enzyme activity at 182 nM and exhibited selective PKD1 inhibition when compared with AKT, polo-like kinase 1 (PLK1), CDK activating kinase (CAK), CAMKIIα, and three different PKC isoforms. Moreover, it was not competitive with ATP for enzyme inhibition. In cell-based assays, CID755673 blocked phorbol ester-induced endogenous PKD1 activation in LNCaP cells in a concentration-dependent manner. Functionally, CID755673 inhibited the known biological actions of PKD1 including phorbol ester-induced class IIa histone deacetylase 5 nuclear exclusion, vesicular stomatitis virus glycoprotein transport from the Golgi to the plasma membrane, and the ilimaquinone-induced Golgi fragmentation. Moreover, CID755673 inhibited prostate cancer cell proliferation, cell migration, and invasion. In summary, our findings indicate that CID755673 is a potent and selective PKD1 inhibitor with valuable pharmacological and cell biological potential.

AB - Protein kinase D (PKD) is a novel family of serine/threonine kinases targeted by the second messenger diacylglycerol. It has been implicated in many important cellular processes and pathological conditions. However, further analysis of PKD in these processes is severely hampered by the lack of a PKD-specific inhibitor that can be readily applied to cells and in animal models. Wenow report the discovery of the first potent and selective cell-active small molecule inhibitor for PKD, benzoxoloazepinolone (CID755673). This inhibitor was identified from the National Institutes of Health small molecule repository library of 196,173 compounds using a human PKD1 (PKCμ)-based fluorescence polarization high throughput screening assay. CID755673 suppressed half of the PKD1 enzyme activity at 182 nM and exhibited selective PKD1 inhibition when compared with AKT, polo-like kinase 1 (PLK1), CDK activating kinase (CAK), CAMKIIα, and three different PKC isoforms. Moreover, it was not competitive with ATP for enzyme inhibition. In cell-based assays, CID755673 blocked phorbol ester-induced endogenous PKD1 activation in LNCaP cells in a concentration-dependent manner. Functionally, CID755673 inhibited the known biological actions of PKD1 including phorbol ester-induced class IIa histone deacetylase 5 nuclear exclusion, vesicular stomatitis virus glycoprotein transport from the Golgi to the plasma membrane, and the ilimaquinone-induced Golgi fragmentation. Moreover, CID755673 inhibited prostate cancer cell proliferation, cell migration, and invasion. In summary, our findings indicate that CID755673 is a potent and selective PKD1 inhibitor with valuable pharmacological and cell biological potential.

UR - http://www.scopus.com/inward/record.url?scp=57749100261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749100261&partnerID=8YFLogxK

U2 - 10.1074/jbc.M805358200

DO - 10.1074/jbc.M805358200

M3 - Article

C2 - 18829454

AN - SCOPUS:57749100261

VL - 283

SP - 33516

EP - 33526

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 48

ER -